Ribo und Boehringer Ingelheim treiben ihr siRNA-Programm zur Behandlung der metabolischen Dysfunktion-assoziierten Steatohepatitis (MASH) weiter voran

PartnershipPositive

AI Analysis

Summary

Ribo and Boehringer Ingelheim announced achievement of a third major milestone in their siRNA program for treating metabolic dysfunction-associated steatohepatitis (MASH).

Outcome Details

Third major milestone achieved in siRNA program development

Importance:5/10

Sentiment:

0.30

siRNAMASHPartnershipDrug Development

Related Companies

$6938

Read the original article

Published by PR Newswire Pharma on May 7, 2026 12:02 PM

Read Original